Literature DB >> 623129

Granulocytopenia in hospitalized patients. II. A prospective comparison of two antibiotic regimens in the empiric therapy of febrile patients.

M Gurwith, J L Brunton, B Lank, A R Ronald, G K Harding, D W McCullough.   

Abstract

The results of empiric antibiotic therapy in 126 hospitalized patients with fever during 192 episodes of granulocytopenia were studied. Febrile granulocytopenic patients were randomly allocated to receive either carbenicillin, methicillin and gentamicin, or carbenicillin and cephalothin. The response rate for the two antibiotic regimens was similar, 49 (60 per cent) of 81 responded to the former and 42 (54 per cent) of 78 to the latter. The response rate in patients receiving other antibiotics because of specific indications or counterindications was 19 (58 per cent) of 33. Thirty-nine (35 per cent) of 110 patients who responded to initial antibiotic therapy had an increase in circulating granulocytes of one log10 or more compared to only 10 (12 per cent) of 79 nonresponders with such an increase. The mortality rate in adult patients receiving carbenicillin, methicillin and gentamicin was eight (16 per cent) of 51, compared to 18 (37 per cent) of 49 in those receiving cephalothin and carbenicillin (P less than 0.05). The significance of this difference in the initial response rate or mortality rate between patients treated with the two antibiotic regimens when only patients with documented bacterial infection were considered. Patients who responded to their initial antibiotic regimen, and patients for whose fever no explanation was found, had the best prognosis.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 623129     DOI: 10.1016/0002-9343(78)90188-2

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  9 in total

Review 1.  [A comparative review of combination therapy: 2 beta-lactams versus beta-lactam plus aminoglycoside].

Authors:  P Dejace; J Klastersky
Journal:  Infection       Date:  1987       Impact factor: 3.553

2.  Gentamicin pharmacokinetics, nephrotoxicity, and prediction of mortality in febrile neutropenic patients.

Authors:  T M Bianco; P N Dwyer; J S Bertino
Journal:  Antimicrob Agents Chemother       Date:  1989-11       Impact factor: 5.191

Review 3.  Empirical antibiotics targeting gram-positive bacteria for the treatment of febrile neutropenic patients with cancer.

Authors:  Ofrat Beyar-Katz; Yaakov Dickstein; Sara Borok; Liat Vidal; Leonard Leibovici; Mical Paul
Journal:  Cochrane Database Syst Rev       Date:  2017-06-03

4.  Comparative study of the serum bactericidal activity of cefoperazone alone and in combination with amikacin or mezlocillin against gram-negative bacilli and Staphylococcus aureus.

Authors:  H Lagast; J Klastersky; H Standiford; A Viollier
Journal:  Infection       Date:  1984 May-Jun       Impact factor: 3.553

5.  Investigations of the occurrence of gentamicin-resistant Staphylococcus aureus.

Authors:  F J Buckwold; W L Albritton; A R Ronald; J Lertzman; R Henriksen
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

6.  Carbenicillin plus cefazolin with or without mecillinam as an early treatment of bacteremia caused by gram-negative organisms: randomized double-blind study.

Authors:  J Klastersky; L Coppens; F Meunier-Carpentier; A P Menday
Journal:  Antimicrob Agents Chemother       Date:  1980-09       Impact factor: 5.191

7.  In vitro and in vivo studies of three antibiotic combinations against gram-negative bacteria and Staphylococcus aureus.

Authors:  S H Zinner; J Klastersky; H Gaya; C Bernard; J C Ryff
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

Review 8.  Gram-negative bacteremia.

Authors:  S C Schimpff
Journal:  Support Care Cancer       Date:  1993-01       Impact factor: 3.603

9.  Infections in acute leukemia: a retrospective study of 148 patients.

Authors:  M S Lee; M D Oh; K W Choe; B K Kim; N K Kim; M Lee
Journal:  Korean J Intern Med       Date:  1986-07       Impact factor: 2.884

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.